Back to companies

Turning Point Therapeutics Inc: Overview

Want to continue viewing company data?

Sign up for exclusive competitive intelligence.
Company Data Subscription $329 per month (billed Annually)
Signup to View Free Sample

Turning Point Therapeutics Inc (TP therapeutics) is a biopharmaceutical company. The company designs and develops clinical stage small molecule, targeted oncology therapies to address key limitations of existing lung cancer therapies. Its pipeline products include Repotrectinib, macrocyclic tyrosine kinase inhibitor; TPX-0022, multi-targeted kinase inhibitor; TPX-0046, a multi-targeted orally bioavailable TKI; TPX - 0131; and ALK inhibitor. TP therapeutics also provides clinical trial activities such as TRIDENT-1 and compassionate use programs. The company’s macrocyclic platform addresses the issues of emerging treatment resistance and toxicities that limit duration of treatment. It operates in the US and Switzerland. TP Therapeutics is headquartered in San Diego, California, the US.

Headquarters United States of America

Address 6150 Lusk Blvd., Suite B100, San Diego, California, 92121


Telephone 1 650 3028388

No of Employees 248

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange TPTX (NASD)

Revenue (2021) $30.8M 23.3% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX -50.4% (2021 vs 2020)

Market Cap* $3.7B

Net Profit Margin (2021) XXX -22.0% (2021 vs 2020)

* As of and is in US$

Explore premium data & analytics

50+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Turning Point Therapeutics Inc’s relevant decision makers and contact details.

30+

Catalyst Calendar

Proactively evaluate Turning Point Therapeutics Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

14+

Pipeline Drugs

Identify which of Turning Point Therapeutics Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

8

Clinical Trials

Determine Turning Point Therapeutics Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

4

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

3

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products
Repotrectinib
TPX-0022
TPX-0046
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Others In March, the company achieved its enrollment target of 40 patients in the EXP-6 cohort of the phase 1/2 registrational TRIDENT-1 study. EXP-6 is comprised of NTRK-positive TKI-pretreated advanced solid tumor patients.
2022 Regulatory Approval In January, the company received clearance from the FDA for the combination of elzovantinib and aumolertinib in EGFR mutant MET-amplified advanced non-small cell lung cancer.
2021 Contracts/Agreements In October, the company announced a clinical collaboration with EQRx to evaluate the combination of Aumolertinib with Elzovantinib to treat advanced non-small cell lung cancer.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Turning Point Therapeutics Inc CytomX Therapeutics Inc Y-mAbs Therapeutics Inc Protagonist Therapeutics Inc BioAtla Inc
Headquarters United States of America United States of America United States of America United States of America United States of America
City San Diego South San Francisco New York Newark San Diego
State/Province California California New York California California
No. of Employees 248 174 148 122 56
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more

Key Financial Charts

Operating Margin
Operating Margin
EPS (Earnings per Share)
EPS (Earnings per Share)
Debt to Equity Ratio
Debt to Equity Ratio
Return on Assets
Return on Assets
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Mark Alles Chairman Executive Board 2021 -
Athena M. Countouriotis, M.D. Director; Chief Executive Officer; President Executive Board 2018 49
Paolo Tombesi Chief Financial Officer; Executive Vice President Senior Management 2021 -
Ed Gemo Chief Information Officer; Senior Vice President Senior Management - -
Mohammad Hirmand Executive Vice President; Chief Medical Officer Senior Management 2018 51
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer